PTC Therapeutics
PTCT
206 hedge funds and large institutions have $2.94B invested in PTC Therapeutics in 2019 Q4 according to their latest regulatory filings, with 57 funds opening new positions, 67 increasing their positions, 60 reducing their positions, and 33 closing their positions.
73% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 33
40% more capital invested
Capital invested by funds: $2.09B → $2.94B (+$842M)
21% more call options, than puts
Call options by funds: $53.6M | Put options by funds: $44.4M
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
12% more funds holding
Funds holding: 184 → 206 (+22)
12% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 60
1.42% less ownership
Funds ownership: 100.6% → 99.18% (-1.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$36.5M |
| 2 |
TCM
TimesSquare Capital Management
New York
|
+$26.7M |
| 3 |
AC
Armistice Capital
New York
|
+$26.4M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$18.4M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$17.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$55.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$48.6M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
-$33.8M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$32.8M |
| 5 |
SCM
Scopia Capital Management
New York
|
-$29.5M |
PTCT Hedge Fund Activity: Q4 2019 in Review
206 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q4 2019, worth a combined $2.94B — up 40% from $2.09B a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new PTCT positions and 33 closed out — a net gain of 24 holders — while 67 added to existing stakes and 60 trimmed.
The largest buyer was Redmile Group, opening a new position worth an estimated $36.5M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $55.9M sold.
- 206 institutional investors held PTC Therapeutics (PTCT) as of Q4 2019, up from 184 in Q3 2019.
- Funds reported $2.94B of PTC Therapeutics stock for Q4 2019, up 40% quarter-over-quarter.
- 57 funds opened new PTC Therapeutics positions in Q4 2019 and 33 closed out, a net change of +24 holders.
- The largest PTC Therapeutics buyer in Q4 2019 was Redmile Group, an estimated $36.5M added.
- The largest PTC Therapeutics seller in Q4 2019 was PFM Health Sciences, an estimated $55.9M sold.
Based on aggregated 13F filings for Q4 2019.